Tetra Bio-Pharma Inc. (TBPMQ)

Overview

Tetra Bio-Pharma Inc. is a pioneering biopharmaceutical entity immersed in the exploration and formulation of cannabinoid-derived medicinal products, with a focus on addressing needs in inflammation, pain management, ophthalmology, and oncology sectors. The firm is making strides in advancing therapeutic solutions with a potent blend of innovative research and strategic partnerships, like that with Cellvera Global Holdings LLC, to escalate the efficacy and application spectrum of its offerings. Located in Orléans, Canada, Tetra Bio-Pharma is at the frontier of leveraging cannabinoids for significant medical interventions, steering groundbreaking research towards improving patient care and outcomes in various complex health conditions.

Products and Services

• PLENITUDE: Designed to alleviate cancer-related pain in patients with advanced stages of the disease, offering a new lease of hope through innovative pain management solutions.
• REBORN: Focuses on the treatment of breakthrough cancer pain, providing rapid relief and improving quality of life for cancer patients facing severe, episodic pain.
• Reduvo: A therapeutic solution aimed at mitigating chemotherapy-induced nausea and vomiting, enhancing patient comfort and adherence to cancer treatment regimens.
• ARDS-003: This product is developed for the treatment of sepsis and the prevention of acute respiratory distress syndrome, showcasing Tetra Bio-Pharma’s commitment to addressing critical care challenges.
• SERENITY: Targets cancer cachexia, a multifaceted syndrome impacting cancer patients, by aiming to restore nutritional balance and improve physical strength.
• PPP003: Designed for the treatment of painful dry eye and uveitis pain, offering relief from chronic eye conditions and enhancing patient quality of life.
• HCC011: Specifically developed for hepatocellular carcinoma, HCC011 represents Tetra Bio-Pharma’s foray into direct cancer treatment, demonstrating its versatility in oncology research.

In addition to these proprietary formulations, Tetra Bio-Pharma Inc. is in collaboration with Cellvera Global Holdings LLC for the co-development of ARDS-003 in tandem with Qifenda 400MG (Favipiravir), a broad-spectrum antiviral drug, broadening its impact on global health crises by combining innovative treatments for enhanced therapeutic outcomes.